Advancing Cancer Treatment with Brilliant Chemistry:
‍Learn About Zentalis' Clinical-Stage Oncology Therapies

Known cancer biology.
Deliberate medicinal chemistry.
Improving patient lives.

About Zentalis

Improving Patient lives

We are a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers.

Learn More

News

Read more

Pipeline

Compound
Indication + Development Approach
Preclinical
Phase 1
Phase 1b
Phase 2
Phase 3

Azenosertib WEE1 Inhibitor

Cyclin E1 Driven Ovarian Cancer
Monotherapy
Phase 2
Uterine Serous Carcinoma
Monotherapy
Phase 2
PARP Resistant Ovarian Cancer
Monotherapy alternating with niraparib or concurrent with niraparib
Phase 2
Platinum Resistant Ovarian Cancer
+ Multiple Chemotherapy Backbones
Phase 1b
Dose Optimization in Solid Tumors
Monotherapy
Phase 1
Osteosarcoma
+ gemcitabine
Phase 1
BRAF Mutant Colorectal Cancer
+ encorafenib and cetuximab
Phase 1
Pancreatic Cancer
+ gemcitabine
Phase 1

ZN-d5 BCL-2 Inhibitor

AL Amyloidosis
Monotherapy
Phase 1
NHL
Monotherapy
Phase 1
AML
+ azenosertib
Phase 1

BCL-xL Degrader

Solid Tumors and Heme Malignancies
Preclinical
Learn More

Join Zentalis

Be part of our vibrant team of dedicated professionals with the common goal of helping cancer patients and make a lasting impact.

Explore Careers